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Background: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment
currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma
conducted in China.
Methods: Several databases were searched from their inception through to August 2014. In order to rate the report
quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or
was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items
(‘randomization’, ‘allocation concealment’, ‘blinding’, ‘baseline characteristics’ and ‘intention-to-treat (ITT) analysis’) were
scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial.
Results: A total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of
4 and a maximum of 11. Some items’ information was insufficient, especially in the categories of ‘trial design’, ‘sample
size’, ‘recruitment’ and ‘ancillary analyses’ with a positive rate of less than 20%. The median MIS was 1 with a minimum
of 0 and a maximum of 3. Some items’ reporting was poor, especially in the categories of ‘randomization’, ‘allocation
concealment and implementation’, ‘blinding’ and ‘ITT analysis’ with a positive rate of less than 10%. The mean OQS
increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001).
With regard to the MIS, no variable was statistically significant in the ordinal regression model.
Conclusion: The reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory
especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of
the CONSORT statement.
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Melasma is an acquired increased pigmentation of the skin
characterized by symmetrical and confluent grey-brown
patches mostly on the areas of the face exposed to the sun,
such as over the cheek bones, forehead, and chin [1].
Although the prevalence of melasma has not been
investigated in most countries, melasma accounts for
about 4 to 10% of new cases in dermatology hospitals
[2] and is most common in Hispanics, darker-skinned
patients, and Asians [3]. In China, the overall prevalence* Correspondence: 5486842@163.com
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unless otherwise stated.of melasma is 3.23 to 13.61%, being 0.36 to 8.33% for
males and 4.65 to 17.98% for females [4,5].
The causes of melasma are still unclear and the treatment
is often unsatisfactory. In general, available therapies consist
of preparations applied to the skin (for example, sunscreens
that block ultraviolet light, topical steroids, topical retinoids,
azelaic acid and kojic acid) and, recently, laser therapy.
In China, internal Chinese medicine, acupuncture, moxi-
bustion and combined therapies are also common in the
treatment of melasma. To find the more efficient therapies,
more and more randomized controlled trials (RCTs) in
melasma have recently emerged. However, it is still
unknown what the reporting quality of RCTs is in
melasma studies conducted in China. RCTs, as a ‘gold
standard’ of evidence-based clinical practice, are generallyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mining efficacy of a new treatment [6]. A well-conducted
RCT reporting on melasma is an effective tool to sci-
entifically present evidence for duplication, experts’
evaluations, peer review decisions and systematic reviews.
Biased results of RCT reports with poor quality will
mislead treatment decisions and the formulation of a
national public health strategy [7,8].
The aim of this study was to assess the quality of
RCT-reporting in the treatment of melasma conducted
in China. Furthermore, we will be able to advise on
improvements in the reporting quality in this field after
we know the status.
Methods
Search strategy
The following databases were searched from their incep-
tion through to August 2014: the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, CINAHL, AMED, the Chinese Biomedical
Database, China National Knowledge Infrastructure,
Wanfang databases and VIP Information. Other resources
were: reference lists of eligible studies and previous
systematic reviews were also reviewed to identify further
eligible studies. The following search terms were used
in Chinese and English: melasma, melanosis, chloasma,
randomized trials, RCT, China, and so on.Table 1 Overall quality of reporting rating using items from t
(CONSORT) statement (n = 246)
Item Criteria Description
1 ‘Randomized’ in the
title or abstract
Study identified as a randomized controlled in t
2 Background Adequate description of the scientific backgroun
of rationale
3 Trial design Description of trial design (such as parallel, facto
allocation ratio
4 Participants Description of the eligibility criteria for participan
5 Interventions Details of the interventions intended for each gr
6 Outcomes Definition of primary (and secondary when approp
7 Sample size Description of sample size calculation
12 Statistical methods Description of the statistical methods used to co
primary outcomes, subgroup analyses, or adjuste
13 Flow chart Details on the flow of participants through each
(number of patients randomly assigned, receivin
completing the protocol and analyzed)
14 Recruitment Dates defining the periods of recruitment and fo
17 Outcomes and
estimation
For each primary and secondary outcome, a sum
each group is given, and the estimated effect si
(for example, 95% CI)
18 Ancillary analyses Clear statement of whether subgroup/adjusted
prespecified or exploratory
19 Harms Description of all important adverse events in eaInclusion and exclusion criteria
Types of studies: RCTs that assessed the effect of any
intervention for melasma conducted in China. However,
quasi-randomized trials, non-randomized, cross-over
RCTs, case reports, and case-control were excluded. All
RCTs had to be performed in China and mainly by
Chinese researchers.
Types of interventions: we considered all types of
interventions; this included studies that compared at
least one active treatment with a control, which may
be a placebo or an alternative intervention.
Types of participants: people of all age groups and ethnic
backgrounds who had a clinical diagnosis of melasma made
by a physician.
Assessment of reporting quality
Rating of overall reporting quality
In order to rate the report quality, we scored 1 for the
item if it was reported in CONSORT 2010 [9,10] and 0
for the item if it was not definitely stated or was not
clear. For overall quality score (OQS), 13 items were
scored and calculated with a range of 0 to 13 (Table 1)
[8,10,11].
Rating of key methodological items
Five key methodological categories of ‘randomization’,






he title or abstract 226 92 1 1
d and explanation 70 29 0.72 0.63 to 0.79
rial) including 5 2 0.69 0.56 to 0.75
ts 194 79 0.93 0.85 to 0.99
oup 244 99 0.75 0.66 to 0.88
riate) outcome measures 201 82 0.83 0.74 to 0.98
0 0 0.76 0.68 to 0.97
mpare groups for
d analyses
241 98 0.81 0.72 to 0.93
stage of the trials
g intended treatment,
242 98 0.95 0.92 to 0.98
llow-up 31 13 0.69 0.60 to 0.78
mary of results for
ze and its precision
244 99 0.82 0.70 to 0.96
analyses were 19 8 0.73 0.65 to 0.83
ch group 113 46 0.78 0.73 to 0.86
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separately because they relate to potential sources of bias
[12-14]. We then developed eight ‘yes’/‘no’ items (Table 2),
wording so that emphasis was placed on quality of
reporting rather than adequacy of trial design. Each
item was scored 1 if the method was appropriate and
0 if inappropriate or if the reporting was unclear. Five
items were scored and a key methodological index score
(MIS) were calculated with range of 0 to 5 for each trial.
Data extraction and analysis
Each article was reviewed by two independent investigators
(YW and TY). Two investigators, blinded to each other’s
ratings, completed the rating form independently. Statistics
used a modified CONSORT checklist with 18 items
(Tables 1 and 2). Cohen’s к-statistic was calculated to
assess agreement between two assessors. Agreement was
judged as poor if к≤ 0.20; fair if 0.20 lower than к≤ 0.40;
moderate if 0.40 lower than к≤ 0.60; substantial if 0.60
lower than к≤ 0.80; good if к higher than 0.80; and perfect
if к = 1 [8,10]. Discrepancies were reviewed in detail and
subsequently settled by consensus.
To explore factors associated with OQS, a multiple
linear regression model was performed only if variables
in the univariate models were significant at P ≤ 0.10. In
the final multivariate model, variables were significant pre-
dictors at P ≤ 0.05. As the OQS variable was in a normal
distribution, we believed that employing a multiple linear
regression model is enough to obtain an approximate
P-value with the clarity of the coefficient interpretation
(not the collinearity relationship between different
independent variables from the result of the collinearity
diagnosis) and the large number of cases (246 cases).
As the outcome variable, MIS could be considered as
a count and the ordinal regression model was used to
select factors associated with MIS. The independent
factors for these models were ‘year of publication’,Table 2 Reporting quality of key methodological items (n = 2
Item Criteria Description
8 Randomization Description of the method used to g
random sequence
9 and 10 Allocation concealment
and implementation
Description of the method used to im
random allocation sequence assuring
until interventions are assigned
11 Blinding Whether or not participants, those ad
interventions, or those assessing the
blinded to group assignment
15 Baseline data An outline of baseline demographic
characteristics of each group
16 Intent-to-treat analysis Number of participants in each grou
each analysis and whether it was don
‘intention-to-treat’‘funding’, ‘type of interventions’ and ‘type of journals’.
Descriptive statistical analysis, linear and ordinal regres-
sion analysis were performed using SPSS version 20.0
(SPSS, Chicago, IL, USA). Analyses of Cohen’s к-statistics
were performed using the SAS software, version 9.3
(SAS Institute, Inc., Cary, NC, USA). Database of RCTs
reporting in the treatment of melasma conducted in China
are provided in Additional file 1.Results
The RCTs selection process is outlined in Figure 1. The
researchers applied the search method to find 567
reports related to the topic. After carefully selecting,
a total of 246 relevant RCTs were included in the final
analysis (Figure 1).Characteristics of included trials
The number of RCT reports on the treatment of
melasma conducted in China is increasing. In the periods
of ‘before 1999’, ‘2000 to 2004’, ‘2005 to 2009’ and
‘2010 to 2014’, 7 articles (2.8%), 13 articles (5.3%), 95
articles (38.6%) and 131 articles (53.3%), respectively
emerged. For the journal type, 67 (27.2%), 45 (18.3%)
and 134 (54.5%) were published in general medical
journals, specialist medical journals and traditional
and alternative medical journals, respectively. In terms
of financial sources, 29 articles (11.8%) reported their
funding sources, most of which were obtained from
provincial and municipal sources. In terms of choice
of interventions, the largest number of interventions
were comprised of internal Chinese medicine (90 reports;
36.6%) followed by combined medicine (40 reports;
16.3%), drugs (25 reports; 10.2%), acupuncture and
moxibustion (23 reports; 9.3%), ultrasonic therapy (6







enerate the 41 17 0.85 0.76 to 0.95
plement the
the concealment
1 0 0.75 0.65 to 0.88
ministering the
outcomes were
6 2 0.78 0.72 to 0.87
and clinical 147 60 0.82 0.78 to 0.90
p included in
e by
5 2 0.86 0.78 to 0.98
Figure 1 Flowchart of the article selection process.
Table 3 Simple linear regression analysis for factors
associated with better overall quality of reporting rating
using items from the Consolidated Standards for
Reporting Trials (CONSORT) statement (n = 246)
Variables SE t P 95% CI
Constant 5.67 0.35 16.0 < 0.001 4.97 to 6.36
Year of publication 0.52 0.10 5.12 < 0.001 0.32 to 0.72
SE, standard error.
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Rating of overall reporting quality
The overall quality of reporting rating using items from
the CONSORT statement was listed in Table 1. The
overall level of reporting was not good; the median OQS
was 7, with a minimum of 4 and a maximum of 11.
Some items’ information was insufficient, especially in
the items of ‘trial design’, ‘sample size’, ‘recruitment’ and
‘ancillary analyses’ with a positive rate of less than 20%.
A substantial agreement was observed for items 2, 3,
5, 7, 14, 18 and 19; a good agreement was observed
for items 4, 6, 12, 13 and 17; a perfect agreement
was observed for item 1.
Rating of key methodological items
The median MIS was 1 with a minimum of 0 and a
maximum of 3. Some items’ reporting was poor, espe-
cially in the items of ‘randomization’, ‘allocation con-
cealment and implementation’, ‘blinding’ and ‘ITT
analysis’ with a positive rate of less than 10% (Table 2).
A substantial agreement was observed for items 9, 10
and 11; a good agreement was observed for item 8,
15 and 16.Exploratory analysis: factors associated with better
reporting quality
In the univariate analysis, year of publication was
the only factor associated with an increased OQS. In
detail, the mean OQS increased by about 0.52 for
manuscripts published in the period of 5-year incre-
ments (95% CI: 0.32 to 0.72; P < 0.001) (Table 3).
With regard to the MIS, no variable was statistically
significant in the ordinal regression model.
Discussion
Our study found that the reporting quality of overall and
key methodological items was not satisfactory in RCTs
Chen et al. Trials  (2015) 16:156 Page 5 of 6of melasma conducted in China. This indicated that
RCTs in this field still needed improvement to meet the
standard of reporting quality required by the CONSORT
statement. There seemed to be an improvement in
time for OQS as the mean OQS increased by about
0.52 for manuscripts published in the period of 5-year
increments, which indicated that more and more
scholars were realizing the importance of reporting in
RCTs due to the widely adoption and promotion of
CONSORT.
However, we identified some items where information
was insufficient or inadequate in most studies, such
as ‘randomization’, ‘allocation concealment and imple-
mentation’, ‘blinding’, ‘ITT analysis’, and so on. These
key methodological items are critical in avoiding
selection, performance/detection, and attrition bias.
An overestimation of treatment effects has been dem-
onstrated in trials with inadequate key methodological
design comparison with trials that adequately reported
these methodological items [15]. Some previous studies
also found it was easy to ignore the reporting importance
of some key methodological items with a positive rate of
less than 30% and similar overall quality of reporting
had the possibility of hiding important differences in
methodological quality [7,8,10,16]. Especially, for stud-
ies in RCTs of melasma mainly conducted outside
China, it is reported that there is a positive rate of
65%, 20% and 95% for items of adequate ‘randomized
sequence generation’, ‘allocation concealment’ and
‘blinding’, respectively [17]. This positive rate is
higher than that in our study. Other studies
[16,18,19] conducted in China in other fields reported
that the categories of ‘randomization’, ‘blinding’ and
‘ITT’ were used in about 15 to 30%, 0 to 20% and 0
to 10% of trials, respectively, which were similar to
the results in our study. Meanwhile, ‘trial design’,
‘sample size’, ‘recruitment’ and ‘ancillary analyses’ should
be emphasized in reports.
One limitation we should point out is that, due to the
language barrier, we did not search for any manuscripts
published in non-Chinese or English journals. This is a
worthwhile area for future study. It remains unknown
whether searching in other language journals would have
altered the constitution of our sample or results.
Despite this limitation, we think our results have
good internal validity. Firstly, it is a meaningful topic
to assess the quality of RCT- reporting in the treatment of
melasma conducted in China as more and more RCTs
in this field are emerging and a full review is lacking.
Secondly, in our survey, the selection and abstraction
processes were independently performed by two qualified
assessors who were well-trained in mastering the
CONSORT statement and have good agreement in item
evaluation reporting.Conclusions
Our findings demonstrate that the reporting quality of
RCTs in the treatment of melasma conducted in China is
lacking especially in key methodological items. Reporting
of RCTs in this field should meet and keep up with the
standards of the CONSORT statement. It is believed that
with the guidance of the CONSORT statement, more and
more high quality RCT-reporting on the treatment of
melasma conducted in China will emerge over time.
Additional file
Additional file 1: RCTs reporting in the treatment of melasma
conducted in China.
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